Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron XBB.1.5-adapted monovalent COVID-19 vaccine
- Development stage
- Approved
- Lead developer
- BioNTech
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular Injection
01
Overview
This vaccine is designed to protect against the Omicron XBB.1.5 variant of SARS-CoV-2. It is an mRNA-based vaccine, developed by companies such as Pfizer/BioNTech and Moderna. The vaccine induces an immune response by encoding the viral spike protein of the XBB.1.5 Omicron variant, helping the body to recognize and fight the virus more effectively. **Developers**: Pfizer/BioNTech and Moderna **Primary Indication**: Prevention of COVID-19 caused by the SARS-CoV-2 virus, particularly the XBB.1.5 variant.
- Brand names
- COMIRNATYSpikevax
- Other names
- XBB.1.5-adapted mRNA COVID-19 vaccine
02
Targets
Cellular lipid membrane80S ribosome (Ribosome and ribosomal components)SARS-CoV-2 spike
Beyond the preview
Go deeper on Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.